and again, slightly revised...... only one thing that cannot be fixed......
Hey Whitten - you've asked a great question there . . . .with >12,000 posts and >150 followers you know the game and are a leader......you know the game far better than most ......my sense is this could easily run to 10 cents plus on FDA OTC Clearance for ActiPatch in the US.
Then a retrace during which the company would reveal its rollout strategy and any major players for marketing and launch timing, retail selling units, etc., could rerun it. I was long a ton in 09 when it ran from .003 to 12.9 cents, didn't get the high, but sold from .08 up. That run was on the basis of speculation about FDA approval for OTC, but many deemed it was early and that FDA did not have the staff, knowledge or pathways established for OTC clearance of a heretofore unknown device.
There were 1Billion shares then + -, and there was no reason why it would not have run to >a buck then. . . . but, as I say it was too early. Now, it is real - FDA hired the staff it said it would, reclassified BIEL ActiPatch as a Class II device, established a new category called SWT from the old PEMF and here we are, waiting patiently for clearance.......
Real question is what would market cap be for a US company with a patented pain relief device with solid efficacy, drug-free, side-effect free, >1million in users hands, >1Billion treatment hours, OTC in 50 countries including Canada and the UK and >140Million Americans suffering from chronic and acute pain today, right now? I say, disruptive technology Tsunami . . . . . hope this helps
